Abstract
Background: The evidence on the efficacy and safety of biosimilar infliximab (IFX) in patients with inflammatory bowel diseases (IBD) is sparse. Metho......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
